Blood Pressure, Safety and Clinical Efficacy of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Trial
Vericiguat showed a slight adjusted decrease in SBP and resulted in more symptomatic hypotension compared with placebo but was overall well-tolerated in a broad population with HFrEF on contemporary therapy even among those predisposed to hypotension. Treatment effects on efficacy outcomes were consistent regardless of baseline SBP.
Authors
- Clara Saldarriaga (ORCID: https://orcid.org/0000-0002-5945-1127)
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Piotr Ponikowski (ORCID: https://orcid.org/0000-0002-3391-7064)
- Alessia Urbinati (ORCID: https://orcid.org/0000-0001-9824-2398)
- Stefano Corda (ORCID: https://orcid.org/0000-0002-8765-2444)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- Eldrin Foster Lewis (ORCID: https://orcid.org/0000-0002-5147-9512)
- Yogesh N.V. Reddy (ORCID: https://orcid.org/0000-0001-5322-0902)
- JoAnn M. Lindenfeld (ORCID: https://orcid.org/0000-0001-9207-3634)
- Ciaran J. McMullan (ORCID: https://orcid.org/0000-0001-7269-6391)
- Maria Borentain
- Vanja Vlajnic (ORCID: https://orcid.org/0000-0002-4004-9226)
- Robert John Mentz (ORCID: https://orcid.org/0000-0002-3222-1719)
- Irina Barash (ORCID: https://orcid.org/0000-0002-0358-6591)
- Kevin J. Anstrom (ORCID: https://orcid.org/0000-0001-6452-2172)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- James E. Udelson (ORCID: https://orcid.org/0000-0003-2998-910X)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- Michele Senni
- Pedro Pinto Teixeira (ORCID: https://orcid.org/0000-0001-5910-1461)
- Carolyn Lam
- Aiwen Xing
- DANIEL M. WOJDYLA (ORCID: https://orcid.org/0009-0009-3431-2014)
- Giuseppe M.C. Rosano
- Christopher M. O'Connor
- Faiez Zannad
- Davis Gates
Institutions
- University of North Carolina at Chapel Hill (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts Medical Center (US)
- University Medical Center Groningen (NL)
- Bayer (United States) (US)
- University of Alberta (CA)
- Inserm (FR)
- National University of Singapore (SG)
- University of Groningen (NL)
- San Raffaele University of Rome (IT)
- University of Mississippi (US)
- Wroclaw Medical University (PL)
- Clinical Research Institute (US)
- Municipality of Medellín (CO)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- Baylor Medical Center at Garland (US)
- Canadian VIGOUR Centre (CA)
- Bayer (Switzerland) (CH)
- Université Bourgogne Franche-Comté (FR)
- Mayo Clinic in Arizona (US)
- IRCCS Ospedale San Raffaele (IT)
- Stanford Medicine (US)
- National Heart Centre Singapore (SG)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Alaska Heart and Vascular Institute (US)
- Research Institute of Dallas (US)
- French Clinical Research Infrastructure Network (FR)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Colorado Anschutz Medical Campus (US)
- University of Milano-Bicocca (IT)
- Bayer (Germany) (DE)
- Université de Lorraine (FR)
- Vanderbilt University Medical Center (US)
- University of Colorado Denver (US)
- Stanford University (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1002/ejhf.70033
- Citations
- 4
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.55